Loading
institutionsInstitution
Newcastle Cancer Centre / Northern Centre for Cancer Care
Newcastle's cancer centre serves the North East and Cumbria; its chemists and pharmacologists discovered rucaparib, the first PARP inhibitor to reach patients, and Ruth Plummer led its first-in-human trial in 2003, while the Wolfson centre leads medulloblastoma research.
Also called: Newcastle upon Tyne Hospitals NHS Foundation TrustFreeman HospitalNewcastle University Centre for Cancer
Overview
The Northern Centre for Cancer Care at the Freeman Hospital and the Great North Children's Hospital provide tertiary cancer care for the North East and Cumbria, while Newcastle University's Centre for Cancer is a Cancer Research UK centre with a drug discovery unit. Newcastle chemists and pharmacologists (Hilary Calvert, Nicola Curtin, Herbie Newell, Bernard Golding) discovered rucaparib with Agouron, and Ruth Plummer led the first-in-human trial of a PARP inhibitor in 2003. The Wolfson Childhood Cancer Research Centre is a leader in medulloblastoma and childhood leukaemia biology, and the Sir Bobby Robson Cancer Trials Research Centre runs early-phase trials. Newcastle also hosts national programmes in ageing and cancer and in mitochondrial disease.
Location
Newcastle upon Tyne, GB
Type
hospital · Newcastle University
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#50 · 52 points (0 Newsweek + 0 NCI + 52 from 26 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Newcastle upon Tyne Hospitals NHS Foundation Trust, including child institutions. 510 works · 4,587 citations · 68% open access · 14% clinical trials · 5% reviews.
Oncology works per year
1162022
1152023
1052024
882025
862026
Most works
- Sanjay Pandanaboyana52 works
- Keith Roberts34 works
- Tobias Menne34 works
- Linda Sharp29 works
- Claire Roddie24 works
- Ricky H. Bhogal23 works
- Alastair Greystoke22 works
- Maeve O’Reilly22 works
- Ruth Plummer22 works
- Wendy Osborne22 works
Most cited
- PARP inhibitor discovery (rucaparib)
- Sir Bobby Robson early-phase trials unit
- Childhood cancer research
- CRUK Newcastle Drug Discovery Unit
Alastair Greystoke
Professor of Precision Oncology, Newcastle University; Consultant Medical Oncologist, Northern Centre for Cancer Care; Clinical Director for Cancer, North East and Yorkshire Genomic Medicine Service
Early-phase lung cancer drug developmentCirculating tumour DNA in the diagnostic pathwayPharmacodynamic biomarkers
The Newcastle oncologist who led the NHS England pilot that put a blood test for lung cancer mutations into the diagnostic pathway, and who co-leads the CONCORDE radiotherapy platform.
Graham H. Jackson
Professor of Clinical Haematology, Newcastle University; Consultant, Freeman Hospital
Multiple myelomaMaintenance therapyLarge pragmatic trials
Led Myeloma XI, the 4,000-patient UK trial that proved lenalidomide maintenance extends survival after transplant.
John Burn
Professor of Clinical Genetics, Newcastle University
Inherited cancer predispositionLynch syndromeChemoprevention
The Newcastle geneticist whose CAPP2 trial showed that two years of aspirin cuts bowel cancer in people born with Lynch syndrome, a result that still shapes NHS advice.
Steven Clifford
Chair of Molecular Paediatric Oncology and Director, Newcastle University Centre for Cancer
MedulloblastomaPaediatric neuro-oncologyMolecular classification
Medulloblastoma biologist whose molecular subgrouping work underpins risk-adapted treatment of childhood brain tumours; directs Newcastle University's cancer centre.
Ruth Plummer
Professor of Experimental Cancer Medicine, Newcastle; Clinical Advisor, Cancer Research UK
Early-phase trialsDNA repair inhibitorsExperimental cancer medicine
Ruth Plummer is an early-phase trialist who ran the first-in-human study of a PARP inhibitor.
Similar pages
- InstitutionUniversity Hospital Southampton / Centre for Cancer Immunology
Shares EUROPAC, AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres.
- InstitutionUniversity Hospitals Birmingham / University of Birmingham Cancer Research Centre
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres, Cancer Research UK.
- InstitutionNottingham University Hospitals Cancer Centre (City Hospital)
Shares EUROPAC, Precision-Panc, UK specialist HPB cancer centres, Basal cell carcinoma.
- InstitutionLeeds Cancer Centre, St James's University Hospital
Shares EUROPAC, AMMF, the Cholangiocarcinoma Charity, UK specialist HPB cancer centres, Basal cell carcinoma.
- InstitutionRoyal Free Hospital, Royal Free London NHS Foundation Trust
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres, Gallbladder cancer.
- InstitutionKing's College Hospital, London
Shares AMMF, the Cholangiocarcinoma Charity, Precision-Panc, UK specialist HPB cancer centres, Gallbladder cancer.
- PersonChristopher Lord
Shares Synthetic lethality, Synthetic lethality approaches, PARP, PARP inhibitors.
- InstitutionGlasgow Royal Infirmary
Shares EUROPAC, Precision-Panc, UK specialist HPB cancer centres, Gallbladder cancer.